In an in vivo study using a mouse model with diabetic kidney disease (DKD), EMPA administration resulted in a marked reduction in tubular injury and ROS levels, as well as upregulation of GPx4 (antioxidant enzyme) [117], indicating an improved equilibrium between ROS and the antioxidant system. The gene discussed is GPX4; the disease is diabetic kidney disease.